RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
BioCryst
Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its third
quarter 2013 financial results will be released on Tuesday, November 5,
2013. BioCryst will host a conference call and webcast at 11:00 a.m.
Eastern Time to discuss the financial results and to provide an update
on the Company's programs. The call will be led by Jon
P. Stonehouse, President and Chief Executive Officer, Thomas
R. Staab, II, Senior Vice President and Chief Financial Officer and Dr.
William P. Sheridan, Senior Vice President and Chief Medical Officer.
Links to a live audio webcast and replay of the presentation may be
accessed on the BioCryst website events page at http://investor.shareholder.com/biocryst/events.cfm.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals designs, optimizes and develops novel small
molecule drugs that block key enzymes involved in infectious and
inflammatory diseases, with the goal of addressing unmet medical needs
of patients and physicians. BioCryst's core development programs include BCX4161
and a next generation oral inhibitor of plasma kallikrein for
hereditary angioedema; peramivir,
a viral neuraminidase inhibitor for the treatment of influenza; and BCX4430,
a broad spectrum antiviral for hemorrhagic fevers. For more information,
please visit the Company's website at www.BioCryst.com.
This press release contains forward-looking statements, including
statements regarding future results and achievements. These statements
involve known and unknown risks, uncertainties and other factors which
may cause our actual results, performance or achievements to be
materially different from any future results, performances or
achievements expressed or implied by the forward-looking statements.
Please refer to the documents BioCryst files periodically with the SEC
and located at http://investor.shareholder.com/biocryst/sec.cfm.
BCRXW
BioCryst Pharmaceuticals
Robert Bennett, +1-919-859-7910
Source: BioCryst Pharmaceuticals
News Provided by Acquire Media